Not recruitingISRCTN54975957
Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial
Research studySouth KoreaSchizophrenia
Understand this study
- Listed locations
- South Korea
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Bundang CHA Hospital (South Korea)
- Sponsor type
- Hospital / academic medical center
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- South Korea
- Age range
- Not clearly listed
- Official registry ID
- ISRCTN54975957
- Official title
Show the full official title
Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
South Korea
Questions about this study
Who is behind this study?
The study sponsor is Bundang CHA Hospital (South Korea), a hospital or academic medical center.
Is this study still recruiting?
The registry lists this study as not recruiting.
